CSTL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CS

Mkt Cap

$976.7M

Volume

255.65K

Next Earnings

November 2nd

Loading chart

CS

CSTLCastle Biosciences, Inc. Common Stock

CSTL

Pay with—

Available Balance0.00

CS

Mkt Cap

$976.4M

Volume

255.65K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Winner of My Stock-Picking Derby Sold Her Top Pick Too SoonHeather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.Investing.com · May 14, 2026

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% RiskCastle Biosciences announced results from the largest prospective multicenter study of its DecisionDx-Melanoma i31-SLNB test, presented at SSO 2026. The study of 912 patients found that patients predicted to have less than 5% risk of sentinel lymph node positivity had an actual positivity rate of 2.6%, with only 1.4% in T1b-T2a tumors. Low-risk patients demonstrated 97.8% three-year recurrence-free survival, supporting the test's ability to identify patients who may safely forgo sentinel lymph node biopsy.GlobeNewswire Inc. · Mar 9, 2026

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic DermatitisCastle Biosciences published a prospective validation study in the Journal of the American Academy of Dermatology showing that its AdvanceAD-Tx gene expression profile test can identify patients with moderate-to-severe atopic dermatitis who are significantly more likely to achieve faster and deeper clinical responses with JAK inhibitor therapy. Approximately 30% of patients studied had a JAK Inhibitor Responder Profile and were 5.5 times more likely to achieve EASI-90 improvement by three months compared to those on Th2-targeted therapies (45.5% vs. 8.3%). The test launched in limited commercial access in late 2025.GlobeNewswire Inc. · Feb 19, 2026

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal CancerA systematic review and meta-analysis demonstrates that TissueCypher® Barrett's Esophagus test can more accurately identify patients at risk of developing esophageal cancer compared to traditional pathology methods.GlobeNewswire Inc. · Dec 12, 2025

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive YearCastle Biosciences has been named a Houston Top Workplace for the fifth consecutive year, earning recognition for employee culture, including awards in Employee Appreciation, Employee Well-Being, and Professional Development.GlobeNewswire Inc. · Nov 17, 2025

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare ConferenceCastle Biosciences announced its Q3 2025 financial results and launched AdvanceAD-Tx, a genetic expression test to help guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis aged 12 and older.GlobeNewswire Inc. · Nov 11, 2025

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s EsophagusCastle Biosciences presented research demonstrating its TissueCypher test can provide advanced risk insights for Barrett's esophagus patients, potentially helping clinicians identify and intervene earlier for patients at higher risk of esophageal cancer progression.GlobeNewswire Inc. · Oct 26, 2025

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025Castle Biosciences will release its Q3 2025 financial results on November 3, 2025, after market close, with a conference call and webcast to discuss the results at 4:30 p.m. Eastern time.GlobeNewswire Inc. · Oct 13, 2025

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025Castle Biosciences was named to Newsweek's inaugural 2025 America's Greatest Companies list, highlighting the company's strong performance in financial strength, workforce dedication, innovation, and corporate sustainability.GlobeNewswire Inc. · Sep 17, 2025

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care DecisionsA study revealed that TissueCypher can identify 15% of non-dysplastic Barrett's esophagus patients with high progression risk to esophageal cancer, potentially enabling more personalized surveillance and treatment strategies.GlobeNewswire Inc. · Sep 9, 2025

to start trading

CS

CSTLCastle Biosciences, Inc. Common Stock

CSTL

Pay with—

Available Balance0.00

Your PositionYou don't own any CSTL yet.

Related Tickers

Earnings